Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Intestinal Malabsorption

In brief

The study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.

Key facts

Study ID

NCT05670951

Run by

Elgan Pharma Ltd.

People needed

360

Starts

2025-02-27

Expected to finish

2029-05-01

Last updated by the study team

2026-01-23

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female pre-term infant 26 and up to 32 weeks gestation. Gestational age matching (±2 weeks) between maternal dates and/or early antenatal ultrasound
• Birth weight ≥ 500g
• Singleton or twin birth

Where it is running

• Laniado Hospital — Netanya, Israel (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.